Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 21, 2025Blood AdvancesOpen Access

Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapy

View Full Paper
Ask AI
Bookmark
Share

Authors

AWAndrew H. WeiPPPanayiotis PanayiotidisPMPau Montesinos

Discussion

Loading...

Member takes

Overview

Prognostic risk categorization shows mixed outcomes in acute myeloid leukemia patients, indicating molecular factors are crucial for treatment with venetoclax.

Key Points

  • To evaluate the prognostic utility of a 4-gene classifier and other molecular factors in AML patients not eligible for intensive chemotherapy.
  • Cohort study of 139 AML patients treated with low-dose cytarabine and venetoclax.
  • Analysis of prognostic markers including complex karyotype and TP53 mutation.
  • Comparison of outcomes using European LeukemiaNet classifications and a 4-gene classifier.
  • Neither ELN 2022 criteria nor the 4-gene classifier adequately stratified prognosis for patients receiving LDAC plus venetoclax.
  • Patients with NPM1 and FLT3-ITD/RAS variants showed high remission rates and long median overall survival.
  • Complex karyotype and presence of TP53 mutation identified as poor prognostic markers.

Cite This Study

Wei et al. (2025) studied this question.

synapsesocial.com/papers/6924e3f2c0ce034ddc34f0bdhttps://doi.org/10.1182/bloodadvances.2025017083
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine2024 · 153 citations
  2. 2Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS2024 · 45 citations
  3. 3Genetic risk stratification in adults with AML receiving venetoclax-based intensive therapy: A real-world study2025
  4. 4Cladribine With Low‐Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia2026 · 1 citations
  5. 5A phase I/II trial of azacitidine and venetoclax in previously untreated Myelodysplastic Syndromes2025 · 1 citations